{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T05:16:29Z","timestamp":1777439789883,"version":"3.51.4"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,10,25]],"date-time":"2018-10-25T00:00:00Z","timestamp":1540425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,10,25]],"date-time":"2018-10-25T00:00:00Z","timestamp":1540425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In ART programs in sub-Saharan Africa, a growing proportion of HIV-infected persons initiating first-line antiretroviral therapy (ART) have a history of prior antiretroviral drug use (PAU). We assessed the effect of PAU on the risk of pre-treatment drug resistance (PDR) and virological failure (VF) in a multicountry cohort of HIV-infected adults initiated on a standard non-nucleoside reverse transcriptase inhibitor (NNRTI)-based first-line ART. Multivariate logistic regression was used to assess the associations between PAU, PDR and VF (defined as viral load \u2265400\u2009cps\/mL). Causal mediation analysis was used to assess the proportion of the effect of PAU on VF that could be eliminated by intervening on PDR. Of 2737 participants, 122 (4.5%) had a history of PAU. Participants with PAU had a 7.2-fold (95% CI 4.4\u201311.7) risk of carrying PDR and a 3.1-fold (95% CI 1.6\u20136.1) increased risk of VF, compared to antiretroviral-na\u00efve participants. Controlling for PDR would eliminate nearly half the effect of PAU on the risk of VF. Patients with a history of PAU are at increased risk of ART failure, which is to a large extent attributable to PDR. These findings support the recent WHO recommendations for use of differentiated, non-NNRTI-based empiric first-line therapy in patients with PAU.<\/jats:p>","DOI":"10.1038\/s41598-018-33538-0","type":"journal-article","created":{"date-parts":[[2018,10,19]],"date-time":"2018-10-19T08:57:11Z","timestamp":1539939431000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Previous antiretroviral drug use compromises standard first-line HIV therapy and is mediated through drug-resistance"],"prefix":"10.1038","volume":"8","author":[{"given":"Seth C.","family":"Inzaule","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cissy M.","family":"Kityo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Siwale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7424-6060","authenticated-orcid":false,"given":"Alani Sulaimon","family":"Akanmu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maureen","family":"Wellington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marleen","family":"de Jager","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prudence","family":"Ive","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kishor","family":"Mandaliya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4418-3713","authenticated-orcid":false,"given":"T. Sonia","family":"Boender","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascale","family":"Ondoa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim C. E.","family":"Sigaloff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denise","family":"Naniche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias F.","family":"Rinke de Wit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raph L.","family":"Hamers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,10,25]]},"reference":[{"key":"33538_CR1","unstructured":"World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection Recommendations for a public health approach - Second edition. at, http:\/\/www.who.int\/hiv\/pub\/arv\/arv-2016\/en\/ (accessed February 16, 2017) (2016)."},{"key":"33538_CR2","unstructured":"World Health Organization. HIV drug resistance report 2017. at, http:\/\/apps.who.int\/iris\/bitstream\/10665\/255896\/1\/9789241512831-eng.pdf?ua=1 (accessed July 26, 2017)."},{"issue":"3","key":"33538_CR3","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/S1473-3099(17)30702-8","volume":"18","author":"Ravindra K Gupta","year":"2018","unstructured":"Gupta, R. K. et al. HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis. Lancet Infect. Dis. https:\/\/doi.org\/10.1016\/S1473-3099(17)30702-8 (2017).","journal-title":"The Lancet Infectious Diseases"},{"key":"33538_CR4","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1093\/cid\/civ556","volume":"61","author":"TS Boender","year":"2015","unstructured":"Boender, T. S. et al. Pretreatment HIV drug resistance increases regimen switches in sub-Saharan Africa. Clin. Infect. Dis. 61, 1749\u20131758 (2015).","journal-title":"Clin. Infect. Dis."},{"key":"33538_CR5","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S1473-3099(11)70255-9","volume":"12","author":"RL Hamers","year":"2012","unstructured":"Hamers, R. L. et al. Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study. Lancet Infect Dis 12, 307\u2013317 (2012).","journal-title":"Lancet Infect Dis"},{"key":"33538_CR6","doi-asserted-by":"publisher","first-page":"e579","DOI":"10.1016\/S2352-3018(16)30119-9","volume":"3","author":"S A\u0301vila-Ri\u0301os","year":"2016","unstructured":"A\u0301vila-Ri\u0301os, S. et al. Pretreatment HIV-drug resistance in Mexico and its impact on the effectiveness of first-line antiretroviral therapy: a nationally representative 2015 WHO survey. Lancet HIV 3, e579\u2013e591 (2016).","journal-title":"Lancet HIV"},{"issue":"8","key":"33538_CR7","doi-asserted-by":"publisher","first-page":"e71407","DOI":"10.1371\/journal.pone.0071407","volume":"8","author":"Jane E. Greig","year":"2013","unstructured":"Greig, J. E. et al. Predictors of Raised Viral Load during Antiretroviral Therapy in Patients with and without Prior Antiretroviral Use: A Cross-Sectional Study. PLoS One 8 (2013).","journal-title":"PLoS ONE"},{"key":"33538_CR8","unstructured":"World Health Organization. Guidelines on the public health response to pretreatment HIV drug resistance at http:\/\/apps.who.int\/iris\/bitstream\/10665\/255880\/1\/9789241550055-eng.pdf?ua=1 (accessed July 25, 2017) (2017)."},{"key":"33538_CR9","unstructured":"Wensing, A. M. et al. 2017 Update of the Drug Resistance Mutations in HIV-1. Top. Antivir. Med. 24, 132\u2013133 (2017)."},{"key":"33538_CR10","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1097\/00002030-200401230-00012","volume":"18","author":"M Violin","year":"2004","unstructured":"Violin, M. et al. Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy. AIDS 18, 227\u2013235 (2004).","journal-title":"AIDS"},{"key":"33538_CR11","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1097\/EDE.0000000000000060","volume":"25","author":"E Suzuki","year":"2014","unstructured":"Suzuki, E., Evans, D., Chaix, B. & VanderWeele, T. J. On the \u2018proportion eliminated\u2019 for risk differences versus excess relative risks. Epidemiology (Cambridge, Mass.) 25, 309\u2013310 (2014).","journal-title":"Epidemiology (Cambridge, Mass.)"},{"key":"33538_CR12","unstructured":"Emsley, R. & Liu, H. PARAMED: Stata module to perform causal mediation analysis using parametric regression models. Statistical Software Components (2013)."},{"key":"33538_CR13","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1001\/jama.2011.375","volume":"305","author":"JZ Li","year":"2011","unstructured":"Li, J. Z. et al. Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. JAMA 305, 1327\u201335 (2011).","journal-title":"JAMA"},{"key":"33538_CR14","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1093\/infdis\/jit635","volume":"209","author":"VF Boltz","year":"2014","unstructured":"Boltz, V. F. et al. Low-frequency nevirapine (NVP)-resistant HIV-1 variants are not associated with failure of antiretroviral therapy in women without prior exposure to single-dose NVP. in. Journal of Infectious Diseases 209, 703\u2013710 (2014).","journal-title":"Journal of Infectious Diseases"},{"key":"33538_CR15","doi-asserted-by":"publisher","unstructured":"Halvas, E. K. et al. Low Frequency Nonnucleoside Reverse\u2010Transcriptase Inhibitor\u2013Resistant Variants Contribute to Failure of Efavirenz\u2010Containing Regimens in Treatment\u2010Experienced Patients. J. Infect. Dis. 100126095936095\u20130 https:\/\/doi.org\/10.1086\/650542 (2010).","DOI":"10.1086\/650542"},{"key":"33538_CR16","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/S1473-3099(11)70149-9","volume":"11","author":"RL Hamers","year":"2011","unstructured":"Hamers, R. L. et al. HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect Dis 11, 750\u2013759 (2011).","journal-title":"Lancet Infect Dis"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-33538-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-33538-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-33538-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T10:43:38Z","timestamp":1671619418000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-33538-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,25]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["33538"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-33538-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,25]]},"assertion":[{"value":"29 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"15751"}}